[
  {
    "sentence": "Next, we evaluated the clinico-pathological factors associated with RANK expression in treatment-naive HER2-positive tumors (Fig. 1c).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel c",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel c",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel c",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "A trend of increased frequency of RANK expression was found in ER/PR negative tumors (p = 0.170 and p = 0.090, respectively), and higher histological grade (p = 0.138) (Fig. 1c).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel c",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel c",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel c",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Similar patterns were observed in tumors resistant to anti-HER2 treatment (Fig. 1c).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel c",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel c",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel c",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Lapatinib treatment, alone or in combination with trastuzumab, resulted in higher RANK mRNA expression in SKBR3 when compared with non-treated cells (Fig. 3a).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "RANK gene and protein expression levels were significantly higher in lapatinib-resistant SKLR and dual lapatinib/trastuzumab-resistant SKLTR cells when compared to SKBR3 parental cells (Fig. 3b, c).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Increased RANK mRNA expression was also observed in BT474 cells with acquired lapatinib resistance (LR) when compared to lapatinib-sensitive parental cells according to public datasets, platform ID: GPL570 [36]; (Fig. 3d), an increase we verified by RT-qPCR (Fig. 3e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel d",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel d",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel d",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Lapatinib-resistant SKLR cells showed higher gene expression levels of RANK, BIRC3, ICAM1, TNFα, and IL8 compared with control SKBR3 cells, and their levels were further increased after pathway stimulation with RANKL, except for IL8 (Fig. 3e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In these cells, BIRC3 expression did not change whereas TNFα was barely expressed (Fig. 3e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Taken together, RANK expression increased after dual treatment with lapatinib and trastuzumab in HER2-positive human breast cancer cell lines, mimicking the results seen in breast cancer samples from the PAMELA trial (Fig. 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Additionally, two HER2-positive cell lines (SKBR3 and BT474) with acquired resistance to lapatinib (SKLR and BTLR) showed increased expression of RANK and several downstream targets, when compared to their respective parental controls (Fig. 3b–e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Lapatinib treatment, alone or in combination with trastuzumab, resulted in higher RANK mRNA expression in SKBR3 when compared with non-treated cells (Fig. 3a).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel a",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "RANK gene and protein expression levels were significantly higher in lapatinib-resistant SKLR and dual lapatinib/trastuzumab-resistant SKLTR cells when compared to SKBR3 parental cells (Fig. 3b, c).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Increased RANK mRNA expression was also observed in BT474 cells with acquired lapatinib resistance (LR) when compared to lapatinib-sensitive parental cells according to public datasets, platform ID: GPL570 [36]; (Fig. 3d), an increase we verified by RT-qPCR (Fig. 3e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel d",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel d",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel d",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Lapatinib-resistant SKLR cells showed higher gene expression levels of RANK, BIRC3, ICAM1, TNFα, and IL8 compared with control SKBR3 cells, and their levels were further increased after pathway stimulation with RANKL, except for IL8 (Fig. 3e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In these cells, BIRC3 expression did not change whereas TNFα was barely expressed (Fig. 3e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel e",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Taken together, RANK expression increased after dual treatment with lapatinib and trastuzumab in HER2-positive human breast cancer cell lines, mimicking the results seen in breast cancer samples from the PAMELA trial (Fig. 2b).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel b",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Additionally, two HER2-positive cell lines (SKBR3 and BT474) with acquired resistance to lapatinib (SKLR and BTLR) showed increased expression of RANK and several downstream targets, when compared to their respective parental controls (Fig. 3b–e).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel b",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "As shown in Fig. 6a, RANK-V5 was detected after immunoprecipitation of HER2 or 611-CTF HER2, but not in 742-NTF or any of the control samples (IgG), indicating that RANK interacts with the carboxy-terminal region of HER2.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel a",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The reverse immunoprecipitation of RANK-V5 corroborated these results (Fig. 6b).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel b",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel b",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "Panel b",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "As seen in Fig. 6c, trastuzumab precipitated endogenous RANK demonstrating that the two receptors physically interact in breast cancer cells in an EGFR-independent manner.",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "Panel c",
        "figure_key": "figure_6"
      }
    ]
  }
]